Anti-FGF23 (Burosumab) in Adult Patients With XLH

NCT04695860 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

X-linked Hypophosphatemia

Interventions

DRUG: Burosumab

Sponsor

Wuerzburg University Hospital

Collaborators

[object Object]